{"entity":{"id":"adg126","kind":"drug","name":"ADG126","aka":[],"tldr":"ADG126 is an experimental monoclonal antibody from Adagene in phase 2 trials for hepatocellular carcinoma, aimed at CTLA-4.","summary":"ADG126 is a monoclonal antibody developed by Adagene and Sanofi. Its target is CTLA-4 (the sponsor names CTLA-4). The sponsor states: A fully human anti-CTLA-4 monoclonal antibody that specifically binds to human CTLA-4. ClinicalTrials.gov describes the intervention as: ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in hepatocellular carcinoma. The largest, NCT05584670, plans to enrol 542 participants with primary completion expected 2027-01-19. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of ADG126","url":"https://clinicaltrials.gov/search?intr=ADG126"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":["ctla4"],"drugs":[],"companies":["sanofi","roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04524871","nct05405595","nct05584670"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"monoclonal antibody","mechanism":"A fully human anti-CTLA-4 monoclonal antibody that specifically binds to human CTLA-4.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/adg126/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"target":[{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"},{"id":"sanofi","kind":"company","name":"Sanofi","route":"/companies/sanofi/"}],"trial":[{"id":"nct05584670","kind":"trial","name":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","route":"/trials/nct05584670/"},{"id":"nct04524871","kind":"trial","name":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li","route":"/trials/nct04524871/"},{"id":"nct05405595","kind":"trial","name":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","route":"/trials/nct05405595/"},{"id":"nct06846268","kind":"trial","name":"Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer","route":"/trials/nct06846268/"}]}}